Dima AbdelMannan1, Warren R. Selman2 and Baha M. Arafah1, 3 Contact Information
(1) Division of Clinical and Molecular Endocrinology, University Hospitals of Cleveland, Case Medical Center, Louis Stokes Cleveland VA Medical Center and Case Western Reserve University, Cleveland, OH, USA
(2) Department of Neurosurgery, University Hospitals of Cleveland, Case Medical Center, and Case Western Reserve University, Cleveland, OH, USA
(3) Division of Endocrinology, University Hospitals/ Case Medical Center, and Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA
Published online: 17 June 2010
Abstract
Management of patients with ACTH producing pituitary adenoma remains to be challenging. Removal of the pituitary adenoma through transsphenoidal surgery is the main stay of treatment.
Complete resection of the adenoma is followed by the development of ACTH deficiency since the normal corticotrophs are suppressed by the pre-existing hypercortisolemia. The concern for ACTH deficiency has led many centers to advocate the use glucocorticoids before, during and after surgery. We provide evidence that such coverage with glucocorticoids is unnecessary until clinical or biochemical documentation of need is established. Given that patients are closely monitored, they are immediately treated with glucocorticoids once they exhibit any clinical and/or biochemical evidence of adrenal insufficiency.
Defining remission in the immediate postoperative period has been rather difficult despite using different biochemical markers. Serum cortisol continues to be the best determinant of disease activity after surgical adenomectomy. However it needs to be interpreted with caution as a biochemical marker of remission in patients given glucocorticoids during and after surgery. Other biochemical markers are also used in the peri-operative period to determine the possibility of remission. These include the dexamethasone suppression test, CRH stimulation without dexamethasone, urinary free cortisol measurements, desmopressin stimulation test, the determination of salivary cortisol and / or plasma ACTH concentrations. Each test has its own advantages and limitations. The simplest and most informative approach is to measure serum cortisol levels repeatedly after surgery without the administration of exogenous glucocorticoids. Low serum cortisol levels (less than 2 ug/dL) in the peri-operative period are highly indicative of surgical success and a high likelihood for clinical remission. Higher serum cortisol levels require careful interpretation and further planning and discussions between the patient and the management team.
Keywords Cushing’s disease - Cushing’s syndrome - Hypercortisolism - ACTH - Cortisol - Adrenal insufficiency - Peri-operative management - Glucocorticoids - Pituitary adenoma - Transsphenoidal surgery - Pituitary adenomectomy
Contact Information Baha M. Arafah
Email: baha.arafah@case.edu
References
1.
Pouratian N, Prevedello DM, Jagannathan J, et al. Outcomes and management of patients with Cushing’s disease without pathological confirmation of tumor resection after transsphenoidal surgery. J Clin Endocrinol Metab. 2007;92:3383–8. 
2.
Arafah BM, Nasrallah MP. Pituitary tumors: pathophysiology, clinical manifestations and management. Endocr-Relat Cancer. 2001;8:287–305.
3.
Findling JW, Raff H. Cushing’s syndrome: important issues in diagnosis and management. J Clin Endocrinol Metab. 2006;91:3746–53.
4.
Boggan JE, Tyrrell JB, Wilson CB. Transsphenoidal microsurgical management of Cushing’s disease. Report of 100 cases. J Neurosurg. 1983;59(2):195–200.
5.
McCance DR, Gordon DS, Fannin TF, Hadden DR, Kennedy L, Sheridan B, et al. Assessment of endocrine function after transsphenoidal surgery for Cushing’s disease. Clin Endocrinol (Oxf). 1993;38(1):79–86.
6.
Lamberts SW, van der Lely AJ, de Herder WW. Transsphenoidal selective adenomectomy is the treatment of choice in patients with Cushing’s disease. Considerations concerning preoperative medical treatment and the long-term follow-up. J Clin Endocrinol Metab. 1995;80:3111–3.
7.
Simmons NE, Alden TD, Thorner MO, Laws Jr ER. Serum cortisol response to transsphenoidal surgery for Cushing disease. J Neurosurg. 2001;95:1–8.
8.
Yap LB, Turner HE, Adams CB, Wass JA. Undetectable postoperative cortisol does not always predict long-term remission in Cushing’s disease: a single centre audit. Clin Endocrinol (Oxf). 2002;56:25–31.
9.
Hammer GD, Tyrrell JB, Lamborn KR, Applebury CB, Hannegan ET, Bell S, et al. Transsphenoidal microsurgery for Cushing’s disease: initial outcome and long-term results. J Clin Endocrinol Metab. 2004;89:6348–57.
10.
Hoybye C, Grenback E, Thoren M, Hulting AL, Lundblad L, von Holst H, et al. Transsphenoidal surgery in Cushing disease: 10 years of experience in 34 consecutive cases. J Neurosurg. 2004;100:634–8.
11.
Rollin GA, Ferreira NP, Junges M, Gross JL, Czepielewski MA, et al. Dynamics of serum cortisol levels after transsphenoidal surgery in a cohort of patients with Cushing’s disease. J Clin Endocrinol Metab. 2004;89:1131–9.
12.
Esposito F, Dusick JR, Cohan P, Moftakhar P, McArthur D, Wang C, et al. Clinical review: early morning cortisol levels as a predictor of remission after transsphenoidal surgery for Cushing’s disease. J Clin Endocrinol Metab. 2006;91:7–13.
13.
Czepielewski MA, Rollin GA, Casagrande A, et al. Criteria of cure and remission in Cushing’s disease: an update. Arq Bras Endocrinol Metabol. 2007;51(8):1362–72. Review.
14.
Krikorian A, Abdelmannan D, Selman WR, Arafah BM. Cushing disease: use of perioperative serum cortisol measurements in early determination of success following pituitary surgery. Neurosurg Focus. 2007;23(3):E6–E11.
15.
Prevedello DM, Pouratian N, Sherman J, et al. Management of Cushing’s disease: outcome in patients with microadenoma detected on pituitary magnetic resonance imaging. J Neurosurg. 2008;109(4):751–9.
16.
Nelson DH, Meakin JW, Thorn GW. ACTH-producing pituitary tumors following adrenalectomy for Cushing’s syndrome. Ann Intern Med. 1960;52:560.
17.
Sonino N, Boscaro M, Fallo F. Pharmacologic management of Cushing syndrome: new targets for therapy. Treat Endocrinol. 2005;4:87–94.
18.
Stalla GK, Stalla J, Huber M, Loeffler JP, Hollt V, von Werder K, et al. Ketoconazole inhibits corticotropic cell function in vitro. Endocrinology. 1988;122:618–23.
19.
Graham KE, Samuels MH, Raff H, Barnwell SL, Cook DM. Intraoperative adrenocorticotropin levels during transsphenoidal surgery for Cushing’s disease do not predict cure. J Clin Endocrinol Metab. 1997;82:1776–9.
20.
Arafah BM, Pearson OH. Cushing’s syndrome. In: Rakel RE, editor. Conn’s current therapy. 36th ed. Philadelphia: WB Saunders Co; 1984. p. 472–7.
21.
Trainer PJ, Lawrie HS, Verhelst J, Howlett TA, Lowe DG, Grossman AB, et al. Transsphenoidal resection in Cushing’s disease: undetectable serum cortisol as the definition of successful treatment. Clin Endocrinol (Oxf). 1993;38:73–8.
22.
Chee GH, Mathias DB, James RA, Kendall-Taylor P. Transsphenoidal pituitary surgery in Cushing’s disease: can we predict outcome? Clin Endocrinol (Oxf). 2001;54:617–26.
23.
Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. N Engl J Med. 2004;350:1629–38.
24.
Coe CL, Murai JT, Wiener SG, Levine S, Siiteri PK. Rapid cortisol and corticosteroid-binding globulin responses during pregnancy and after estrogen administration in the squirrel monkey. Endocrinology. 1986;118:435–40.
25.
Orbach O, Schussler GC. Increased serum cortisol binding in chronic active hepatitis. Am J Med. 1989;86:39–42.
26.
Abdelmannan D, Krikorian A, Selman WR, Arafah BM. Measurements of plasma ACTH in the peri-operative period can predict the long-term outcome of surgically-treated patients with ACTH-secreting adenomas (Cushing’s Disease) OR40-6. Proceedings of the 90th Endocrine Society meeting in San Francisco, CA; June 2008.
27.
Chen JC, Amar AP, Choi S, Singer P, Couldwell WT, Weiss MH. Transsphenoidal microsurgical treatment of Cushing disease: postoperative assessment of surgical efficacy by application of an overnight low-dose dexamethasone suppression test. J Neurosurg. 2003;98(5):967–73.
28.
Invitti C, Pecori Giraldi F, de Martin M. Diagnosis and management of Cushing’s syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic–Pituitary–Adrenal Axis. J Clin Endocrinol Metab. 1999;84(2):440–8.
29.
Banerjee A, Martin N, Dhillo W, Roncaroli F, Meeran K. Use of the dexamethasone-suppressed corticotrophin-releasing hormone test to predict cure in patients with Cushing’s disease following pituitary surgery, in Society for Endocrinology BES. Birmingham, UK, 2007.
30.
Newell-Price J, Perry L, Medbak S, et al. A combined test using desmopressin and corticotropin releasing hormone in the differential diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab. 1997;82:176–81.
31.
Malerbi DA, Mendonc BB, Lieberman B, Toledo SPA, Corradini MCM, Cunha-Neto MB, et al. The desmopressin stimulation test in the differential diagnosis of Cushing’s syndrome. Clin Endocrinol. 1993;38:463–72.
32.
Colombo P, Dall’Asta C, Barbetta L, et al. Usefulness of the desmopressin test in the postoperative evaluation of patients with Cushing’s disease. Eur J Endocrinol. 2003;143:227–34.
33.
Losa M, Mortini P, Dylgjeri S. Desmopressin stimulation test before and after pituitary surgery in patients with Cushing’s disease. Clin Endocrinol. 2006;55:61–8.
34.
Friedman RB, Oldfield EH, Nieman LK, Chrousos GP, Doppman JL, Cutler Jr GB, et al. Repeat transsphenoidal surgery for Cushing’s disease. J Neurosurg. 1989;71:520–7.
35.
Ram Z, Nieman LK, Cutler Jr GB, Chrousos GP, Doppman JL, Oldfield EH, et al. Early repeat surgery for persistent Cushing’s disease. J Neurosurg. 1994;80:37–45.
36.
Benveniste RJ, King WA, Walsh J, Lee JS, Delman BN, Post KD. Repeated transsphenoidal surgery to treat recurrent or residual pituitary adenoma. J Neurosurg. 2005;102:1004–12.
37.
Locatelli M, Vance ML, Laws ER. Clinical review: the strategy of immediate reoperation for transsphenoidal surgery for Cushing’s disease. J Clin Endocrinol Metab. 2005;90:5478–82.
No comments:
Post a Comment